MKL2 Antibody

Code CSB-PA891962LA01HU
Size US$166
Order now
Image
  • Western Blot
    Positive WB detected in: Hela whole cell lysate, NIH/3T3 whole cell lysate
    All lanes: MKL2 antibody at 4.2μg/ml
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 119, 43, 52, 115, 120 kDa
    Observed band size: 119 kDa

  • IHC image of CSB-PA891962LA01HU diluted at 1:500 and staining in paraffin-embedded human melanoma performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) MKL2 Polyclonal antibody
Uniprot No.
Target Names
MKL2
Alternative Names
FLJ31823 antibody; Megakaryoblastic leukemia 2 antibody; megakaryoblastic leukemia 2 protein antibody; MKL/myocardin-like 2 antibody; MKL/myocardin-like protein 2 antibody; Mkl2 antibody; MKL2_HUMAN antibody; MRTF-B antibody; Myocardin-related transcription factor B antibody; NPD001 antibody
Raised in
Rabbit
Species Reactivity
Human, Mouse
Immunogen
Recombinant Human MKL/myocardin-like protein 2 protein (164-313AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The MKL2 Antibody (Product code: CSB-PA891962LA01HU) is Non-conjugated. For MKL2 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA891962LB01HU MKL2 Antibody, HRP conjugated ELISA
FITC CSB-PA891962LC01HU MKL2 Antibody, FITC conjugated
Biotin CSB-PA891962LD01HU MKL2 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA, WB, IHC
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:500-1:1000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Acts as a transcriptional coactivator of serum response factor (SRF). Required for skeletal myogenic differentiation.
Gene References into Functions
  1. Taken together, these findings suggest that MKL1 and MKL2 are present at synapses and involved in dendritic spine maturation. PMID: 29335431
  2. Study showed that MRTF-A and MRTF-B were upregulated in pancreatic cancer tissues supporting the hypothesis that both of them are oncogenes in pancreatic cancer. PMID: 26498848
  3. While disruption of the MKL2:SRF axis has been associated with severe microcephaly and disordered brain development in multiple model systems, the role of this transcription factor complex has not been previously demonstrated in human brain development. PMID: 23692340
  4. There were multiple independent HIV integrations in several genes, including MKL2 and BACH2; many of these integrations were in clonally expanded cells. PMID: 24968937
  5. MKL1/2 depletion resulted in Ras activation, elevated p16 expression and hypophosphorylation of the retinoblastoma (Rb) protein in DLC1-deficient hepatocellular carcinoma cells. PMID: 23853104
  6. Based on a recurrent translocation t(11;16)(q13;p13), the C11orf95-MKL2 fusion gene has been found in eight further cases of chondroid lipomas. PMID: 23672313
  7. study provides evidence that MKL1/2 mediates cancerous transformation in DLC1-deficient hepatocellular and mammary carcinoma cells PMID: 22139079
  8. C11orf95-MKL2 is the resulting fusion oncogene of t(11;16)(q13;p13) in chondroid lipoma. PMID: 20607705
  9. dominant negative MKL2 blocked differentiation-induced expression of SRF target genes skeletal alpha-actin and alpha-myosin heavy chain and blocked differentiation of the myoblasts to myotubes in vitro. PMID: 14565952
  10. BMP signaling modulates VSMC phenotype via cross-talk with the RhoA/MRTFs pathway, and may contribute to the development of the pathological characteristics observed in patients with PAH and other obliterative vascular diseases. PMID: 17947237
  11. Myocardin-related transcription factors are critical mediators of transforming growth factor beta (TGF-beta) 1-induced epithelial-mesenchymal transition.[ PMID: 18056415
  12. RNA interference was used to investigate the contribution of the MRTF-SRF pathway to cytoskeletal dynamics in MDA-MB-231 breast carcinoma and B16F2 melanoma cells, in which basal MRTF-SRF activity is Rho-dependent. PMID: 19198601

Show More

Hide All

Involvement in disease
A chromosomal aberration involving C11orf95 is found in 3 chondroid lipomas. Translocation t(11;16)(q13;p13) with C11orf95 produces a C11orf95-MKL2 fusion protein (PubMed:20607705).
Subcellular Location
Nucleus.
Database Links

HGNC: 29819

OMIM: 609463

KEGG: hsa:57496

STRING: 9606.ENSP00000339086

UniGene: Hs.49143

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*